⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 5, 2018Diabetes Obesity and MetabolismOpen Access

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

View Full Paper

Ask AI

Bookmark

Share

Abstract

PIONEER 6 will provide evidence regarding the CV safety of oral semaglutide in patients with type 2 diabetes and high CV risk.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bain et al. (2018) studied this question.

synapsesocial.com/papers/69d91c61ea2783c07da3c208 https://doi.org/10.1111/dom.13553

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

18. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2018</i>Original Research · 2017 · 708 citations
2Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitorsReview · 2015 · 435 citations
3Treatment Patterns Among Older Patients with Type 2 Diabetes in the United States: A Retrospective Cohort StudyRetrospective Study · 2014 · 6 citations
4Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organizationOriginal Research · 2009 · 78 citations
5Oral Delivery of Glucagon-like Peptide-1 and Analogs: Alternatives for Diabetes Control?Original Research · 2012 · 49 citations